Literature DB >> 11600400

In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

A Gikas1, I Spyridaki, E Scoulica, A Psaroulaki, Y Tselentis.   

Abstract

The in vitro susceptibility to linezolid shown by nine Greek isolates of Coxiella burnetii derived from patients with acute Q fever was investigated. MICs of linezolid were compared with those of pefloxacin, ciprofloxacin, ofloxacin, trovafloxacin, doxycycline, and clarithromycin using the shell vial assay. MICs of linezolid and clarithromycin ranged from 2 to 4 microg/ml; those of doxycycline, trovafloxacin, and ofloxacin ranged from 1 to 2 microg/ml; those of pefloxacin ranged from 1 to 4 microg/ml; and those of ciprofloxacin ranged from 4 to 8 microg/ml. Linezolid was effective in controlling intracellular parasites in cultures of Vero cells infected by C. burnetii. No bactericidal activity by linezolid was obtained against C. burnetii at 8 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600400      PMCID: PMC90826          DOI: 10.1128/AAC.45.11.3276-3278.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Linezolid and reversible myelosuppression.

Authors:  S L Green; J C Maddox; E D Huttenbach
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

2.  Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm.

Authors:  M Maurin; A M Benoliel; P Bongrand; D Raoult
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

Review 3.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Treatment of Q fever.

Authors:  D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 5.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

6.  In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.

Authors:  H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones.

Authors:  M R Yeaman; L A Mitscher; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

9.  Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases.

Authors:  Y Tselentis; A Gikas; D Kofteridis; E Kyriakakis; N Lydataki; D Bouros; N Tsaparas
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431

View more
  7 in total

Review 1.  Q fever in adults: review of 66 clinical cases.

Authors:  M Sampere; B Font; J Font; I Sanfeliu; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

Review 2.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  Antimicrobial therapies for Q fever.

Authors:  Gilbert J Kersh
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09-27       Impact factor: 5.091

4.  Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.

Authors:  Jean-Marc Rolain; Areen Boulos; Marie-Noëlle Mallet; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells.

Authors:  Frédéric Peyrusson; Adam O Whelan; Margaret G Hartley; Isobel H Norville; Sarah V Harding; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-09-20       Impact factor: 5.191

6.  Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Authors:  Ioanna Spyridaki; Anna Psaroulaki; Iosif Vranakis; Yannis Tselentis; Achilleas Gikas
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

7.  Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.

Authors:  Marissa S Fullerton; Punsiri M Colonne; Amanda L Dragan; Katelynn R Brann; Richard C Kurten; Daniel E Voth
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.